non-opiate treatment after prenatal opiate exposure to prevent postnatal injury to the young brain

Conditions: Neonatal Abstinence Syndrome

Summary: the long term goals of our research are to establish the best pharmacological treatment for nas and determine how pharmacologic treatment of nas affects long-term developmental outcomes. the objective of this application is to evaluate the effectiveness of clonidine as a treatment for neonates with nas, in a randomized clinical trial. our central hypothesis is that clonidine will effectively treat drug withdrawal manifestations in neonates.

in this current proposal, the research plan is based on our pilot study, which randomized infants with nas to receive morphine or clonidine. the treatment groups were similar as to mean birth weight, gestational age, apgar scores, and postnatal age at treatment. infants enrolled had no other medical or surgical complications. treatment was initiated per our nicu standard at the time, and will be continued in this protocol. total los was shorter by about 1 week in the clonidine (mean of 15 days), compared to 21 days in the morphine group. aims and objectives: to determine whether the treatment of nas with a non-opiate medication, clonidine, will be more effective than morphine * compare clonidine and morphine for the treatment of nas. compare the efficacy of each drug which is determined by duration of treatment in number of days, number of dose escalations needed to achieve needed treatment, and the need for second drug treatment. * evaluate the neurobehavioral performance scores (habituation, orientation, self- regulation, motor/reflexes, and stress/ abstinence scales) using the neonatal intensive care (nicu) network neurobehavioral scale (nnns) in both treatment groups. this exam will take place after treatment begins, and at one month post-natal age (38-44 weeks post menstrual age) or at discharge, whichever comes first. to determine whether treatment of nas with clonidine will result in better early childhood outcomes than those treated with morphine • compare the cognitive, motor and behavioral development of children in both treatment groups using the bayley iii scales of infant development at 6 months, one and two years of age. to build population pharmacokinetic/pharmacodynamic models and determine factors that affect exposure and response to morphine and clonidine • measure blood levels obtained at random times and correlate to finnegan scores. the pharmacodynamics may help with understanding nas medications and coping measures in babies.

Eligibility criteria:
inclusion criteria: * gestational age (ga) \> or equal to 35 weeks * known prenatal opiate exposure (by mother admitting use, mom with positive opiate screen during pregnancy, or positive neonatal urine and meconium screening) * no known prenatal cocaine exposure * no morphine or clonidine dose before enrollment * symptomatic with finnegan scores (fs): 3 consecutive scores greater than or equal to 8, or 2 consecutive scores greater than or equal to 12, and/or with attending decision to treat for nas * less than or equal to 7 days of age * attending physician decides to start pharmacologic treatment and agrees to infant's study participation exclusion criteria: * seizures * major congenital malformations * blood pressure instability * major medical condition in addition to nas * parents unable to understand english

Keywords: opiate use during pregnancy clonidine morphine prenatal opiate neonatal abstinence syndrome infant, newborn, diseases substance-related disorders chemically-induced disorders opiate alkaloids mental disorders narcotics central nervous system depressants physiological effects of drugs adrenergic alpha-2 receptor agonists adrenergic alpha-agonists molecular mechanisms of pharmacological action antihypertensive agents analgesics peripheral nervous system agents sympatholytics autonomic agents neurotransmitter agents